Related Experiment Video
Updated: Feb 4, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial
Iris Baumgartner1, Lars Norgren2, F Gerry R Fowkes3
1Swiss Cardiovascular Centre, Inselspital, Division of Angiology, Bern University Hospital, University of Bern, Bern, Switzerland.
Insights
Lower extremity revascularization (LER) in peripheral artery disease (PAD) patients increased risks for major cardiovascular events and major adverse limb events (MALE). Endovascular LER was most common, but both surgical and endovascular procedures carried significant risks.
Area of Science:
- Vascular Surgery
- Cardiology
- Clinical Trials
Background:
- Peripheral artery disease (PAD) management often involves lower extremity revascularization (LER).
- Long-term outcomes and predictors of LER in PAD patients remain incompletely understood.
- The EUCLID trial provides a platform to investigate LER outcomes in a large PAD cohort.
Purpose of the Study:
- To analyze lower extremity revascularization (LER) in the EUCLID trial.
- To identify predictors of LER in patients with peripheral artery disease (PAD).
- To evaluate cardiovascular and limb-related outcomes following LER.
Main Methods:
- Analysis of patients undergoing post-randomization LER (n=1,738) versus no LER (n=12,147) from the EUCLID trial.
- Assessment of independent predictors for LER using univariable and multivariable models.
- Primary endpoint: myocardial infarction, ischemic stroke, or cardiovascular death. Major adverse limb events (MALE): acute limb ischemia or major amputation.
Main Results:
- Post-randomization LER occurred in 12.5% of patients, predominantly endovascular (74.7%).
- Independent LER predictors included prior LER, geographic region, limb symptoms, diabetes, and smoking.
- LER was associated with increased risk for primary endpoint (HR 1.60) and MALE (HR 12.0).
Conclusions:
- Lower extremity revascularization (LER) in PAD patients, most often endovascular, is linked to higher risks of cardiovascular events and MALE.
- Surgical LER showed numerically higher primary endpoint event rates, while MALE rates were similar between endovascular and surgical approaches.
- These findings highlight the significant risks associated with LER in PAD patients, underscoring the need for careful consideration of treatment strategies.
Background:
Lower extremity revascularization (LER) is a common treatment in patients with peripheral artery disease (PAD), but long-term outcomes are poorly defined.
Objectives:
The aim was to analyze LER in the EUCLID (Examining Use of tiCagreLor In paD) trial to determine predictors and cardiovascular outcomes.
Methods:
Patients were grouped according to whether they received a post-randomization LER (n = 1,738) or not (n = 12,147). All variables were assessed for significance in univariable and parsimonious multivariable models. The primary endpoint was myocardial infarction, ischemic stroke, or cardiovascular death; major adverse limb events (MALE) included acute limb ischemia or major amputation.
Results:
A post-randomization LER occurred in 12.5% of patients and was an endovascular LER in 74.7%. Endovascular LERs were performed more often in North America, whereas surgical procedures occurred more frequently in Europe. Independent factors predicting LER were prior and type of prior LER, geographic region, limb symptoms, diabetes, and smoking. A post-randomization LER was associated with an increased risk for the primary endpoint (hazard ratio: 1.60; 95% confidence interval: 1.35 to 1.90; p < 0.0001) and MALE (hazard ratio: 12.0; 95% confidence interval: 9.47 to 15.30; p < 0.0001). Event rates for the primary endpoint after LER were numerically higher in the surgical subgroup, but MALE were similar between surgical and endovascular LER.
Conclusions:
In the EUCLID trial, LER was most often endovascular. Following LER, there was an increased hazard for the primary endpoint (with higher event rates in the surgical group) and a markedly increased risk for MALE events (with similar event rates between surgical and endovascular LER procedures). (A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease [EUCLID]; NCT01732822).
Related Concept Videos
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Absolute and Local Extreme Values

